PL2274422T3 - Wektor ekspresyjny - Google Patents

Wektor ekspresyjny

Info

Publication number
PL2274422T3
PL2274422T3 PL09733074T PL09733074T PL2274422T3 PL 2274422 T3 PL2274422 T3 PL 2274422T3 PL 09733074 T PL09733074 T PL 09733074T PL 09733074 T PL09733074 T PL 09733074T PL 2274422 T3 PL2274422 T3 PL 2274422T3
Authority
PL
Poland
Prior art keywords
expression vector
vector
expression
Prior art date
Application number
PL09733074T
Other languages
English (en)
Inventor
Yuko Shimatani-Shibata
Hitomi Shimizu
Hiromi Yonekura
Original Assignee
Anaeropharma Science, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaeropharma Science, Inc. filed Critical Anaeropharma Science, Inc.
Publication of PL2274422T3 publication Critical patent/PL2274422T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL09733074T 2008-04-17 2009-04-16 Wektor ekspresyjny PL2274422T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12452808P 2008-04-17 2008-04-17

Publications (1)

Publication Number Publication Date
PL2274422T3 true PL2274422T3 (pl) 2017-09-29

Family

ID=40792658

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09733074T PL2274422T3 (pl) 2008-04-17 2009-04-16 Wektor ekspresyjny
PL09733604T PL2280717T3 (pl) 2008-04-17 2009-04-17 Środek terapeutyczny dla chorób beztlenowych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL09733604T PL2280717T3 (pl) 2008-04-17 2009-04-17 Środek terapeutyczny dla chorób beztlenowych

Country Status (12)

Country Link
US (3) US8383398B2 (pl)
EP (2) EP2274422B1 (pl)
JP (3) JP5735804B2 (pl)
KR (3) KR101674977B1 (pl)
CN (2) CN102046791B (pl)
CA (2) CA2721653C (pl)
DK (2) DK2274422T3 (pl)
ES (2) ES2628378T3 (pl)
HU (2) HUE033561T2 (pl)
PL (2) PL2274422T3 (pl)
PT (2) PT2274422T (pl)
WO (2) WO2009128272A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033561T2 (hu) * 2008-04-17 2017-12-28 Anaeropharma Science Inc Expresszió vektor
US9730968B2 (en) 2008-04-17 2017-08-15 Anaeropharma Science, Inc. Therapeutic agent for ischemic diseases
US20130095072A1 (en) * 2010-01-29 2013-04-18 Anaeropharma Science, Inc. Therapeutic agent for ischemic diseases
US8338162B2 (en) * 2009-04-17 2012-12-25 Anaeropharma Science, Inc. Obligately anaerobic mutant lactic acid bacterium and preparation method therefor, and expression vector functioning in obligately anaerobic lactic acid bacterium
KR101850162B1 (ko) * 2010-01-29 2018-04-18 가부시키가이샤 아네로파마·사이엔스 형질전환용 플라스미드
CN103958680A (zh) * 2011-07-13 2014-07-30 阿内罗药物科学株式会社 缺血性疾病治疗药
DK3228706T3 (da) 2014-12-03 2021-07-26 Azusapharma Sciences Inc Coekspressionsplasmid
SG11201705915VA (en) * 2015-01-19 2017-08-30 Univ Shinshu Therapeutic agent for ischemic diseases
LU100900B1 (de) * 2018-08-10 2020-02-17 Thomas Melchior Homann Verbindungen zur modulation von a-ketoglutarsäure (2kg)-abhängigen oxygenasen
US20220281998A1 (en) 2019-08-28 2022-09-08 Azusapharma Sciences, Inc. Bifidobacterium spp. expressing and secreting diabody-type bsab
CN112999215B (zh) * 2019-12-20 2024-06-21 复旦大学 呋喃酮糖苷类化合物的应用
CN115400154A (zh) * 2022-08-10 2022-11-29 深圳未知君生物科技有限公司 长双歧杆菌在制备治疗自闭症谱系障碍的药物中的应用
WO2024187069A1 (en) * 2023-03-08 2024-09-12 University Of Florida Research Foundation, Incorporated Engineering enterobacteria to site-specifically activate the anticancer prodrug 5-fluorocytosine for treating colon cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8713601D0 (en) * 1987-06-10 1987-07-15 Unilever Plc Fermentation
WO1991009131A1 (en) * 1989-12-20 1991-06-27 Valio Finnish Cooperative Dairies Association Cloning vector for use in lactic acid bacteria
US6416754B1 (en) 1994-03-03 2002-07-09 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
US6984513B2 (en) 1994-03-03 2006-01-10 The Board Of Trustees Of The Leland Stanford Junior University Anaerobe targeted enzyme-mediated prodrug therapy
TW357191B (en) * 1996-06-04 1999-05-01 Food Industry Development Res Institute Bifidobacteria strains with acid, bile salt and oxygen tolerance and their culture method the invention relates to bifidobacteria strains with acid, bile salt and oxygen tolerance and their culture method
JP2000060541A (ja) * 1998-08-27 2000-02-29 Fuyuki Mitsuyama ビフィズス菌増殖促進物質と整腸物質とビフィズス菌製剤
US20020054865A1 (en) * 2000-09-21 2002-05-09 Minoru Fujimori Anaerobic bacterium as a drug for cancer gene therapy
JP3642755B2 (ja) 2000-09-21 2005-04-27 純 天野 嫌気性菌を用いた遺伝子治療用医薬
DK1355566T3 (da) * 2000-12-18 2013-03-04 Univ Texas Lokal regional kemoterapi og radioterapi ved anvendelse af hydrogel in situ
KR100457879B1 (ko) * 2001-02-24 2004-11-18 주식회사 비피도 비피도박테리움 유래 신규 플라스미드, 이를 이용한 재조합 발현 벡터 및 형질전환 방법
WO2006057289A1 (ja) 2004-11-24 2006-06-01 Anaeropharma Science Inc. 新規シャトルベクター
AU2006206393B2 (en) * 2005-01-21 2010-04-08 The Research Foundation Of State University Of New York Methods for treating adhesive capsulitis
CA2603453C (en) * 2005-04-08 2015-01-27 Yoshinori Hamaji 5-fluorouracil-resistant bacteria and method for production thereof
AU2007230844A1 (en) * 2006-03-27 2007-10-04 Government Of The United States Of America, As Represented By The Secretary Tetracycline compounds and methods of treatment
BRPI0709946A2 (pt) * 2006-04-13 2011-08-02 Ambrozea Inc composições e métodos para produzir produtos e resìduos de fermentação
US8911721B2 (en) 2006-05-24 2014-12-16 Anaeropharma Science, Inc. Method of constructing gene transport support
HUE033561T2 (hu) * 2008-04-17 2017-12-28 Anaeropharma Science Inc Expresszió vektor

Also Published As

Publication number Publication date
KR101674977B1 (ko) 2016-11-10
EP2280717B1 (en) 2018-05-30
JP5735804B2 (ja) 2015-06-17
JP5514735B2 (ja) 2014-06-04
US20110110893A1 (en) 2011-05-12
CN102046190B (zh) 2013-03-13
WO2009128275A9 (en) 2010-11-11
US20130122582A1 (en) 2013-05-16
PL2280717T3 (pl) 2018-10-31
KR20110021784A (ko) 2011-03-04
PT2274422T (pt) 2017-06-28
EP2280717A1 (en) 2011-02-09
US8470311B2 (en) 2013-06-25
WO2009128272A1 (en) 2009-10-22
JP6089025B2 (ja) 2017-03-01
JP2011518112A (ja) 2011-06-23
US20090264513A1 (en) 2009-10-22
WO2009128275A1 (en) 2009-10-22
EP2274422B1 (en) 2017-03-15
US8383398B2 (en) 2013-02-26
WO2009128272A9 (en) 2010-11-11
ES2628378T3 (es) 2017-08-02
HUE033561T2 (hu) 2017-12-28
CN102046791B (zh) 2013-09-18
HUE039768T2 (hu) 2019-02-28
CA2721664A1 (en) 2009-10-22
ES2686080T3 (es) 2018-10-16
WO2009128272A4 (en) 2010-02-18
KR101671283B1 (ko) 2016-11-02
JP2015091243A (ja) 2015-05-14
DK2280717T3 (en) 2018-09-10
KR20100134765A (ko) 2010-12-23
CN102046190A (zh) 2011-05-04
KR20160102584A (ko) 2016-08-30
EP2274422A1 (en) 2011-01-19
WO2009128275A4 (en) 2010-02-18
DK2274422T3 (en) 2017-07-03
CA2721664C (en) 2018-01-23
PT2280717T (pt) 2018-10-04
CA2721653A1 (en) 2009-10-22
CA2721653C (en) 2018-03-20
JP2011517929A (ja) 2011-06-23
CN102046791A (zh) 2011-05-04

Similar Documents

Publication Publication Date Title
PL2918172T3 (pl) Połączenia środków kontroli biologicznej i fungicydów
GB0810912D0 (en) Vector
PL2274422T3 (pl) Wektor ekspresyjny
GB0820631D0 (en) Vectors
SI2367943T1 (sl) Sesalski ekspresijski vektor
GB0808924D0 (en) Raingen
GB0807353D0 (en) Suit-match
GB0804525D0 (en) Lamstone
GB0815689D0 (en) Photbioreactors
GB0810154D0 (en) Expression vector
GB0804158D0 (en) Fencemate
GB0823425D0 (en) Vectors
GB0709375D0 (en) Vector
GB2462330B (en) Suit
GB0804837D0 (en) Concept three
GB0808629D0 (en) Prambrella
GB0811485D0 (en) Corcostpre010
GB0802182D0 (en) Smartspa
GB0802323D0 (en) Cable-routing
GB0802462D0 (en) Aerpurifiers
GB0800635D0 (en) Combi-cutter
GB0804418D0 (en) Easyparker
AU323550S (en) Sidechair
GB0800723D0 (en) Myloo
GB0806221D0 (en) Pillexpeller